Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris
Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment. One reference lesion is clinically evaluated with pictures.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris|
- Repigmentation percentage of the reference lesion after 6 months.
- Number of patients with repigmentation after 3 and 6 months.
- Repigmentation percentage of the reference lesion after 3 months.
- Adverse events (month 3 and 6).
|Study Start Date:||May 2004|
|Study Completion Date:||November 2004|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00372307
|University Hospital Ghent|
|Ghent, Belgium, 9000|
|Principal Investigator:||Jean-Marie Naeyaert, MD, PhD||University Hospital, Ghent|